Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Especially after the week Teva’s had, it may need to pay up—big time—to land a CEO that can help it turn its fortunes.

Allergan’s catching a break this year, and it’s one that Thursday allowed it to hike its guidance for 2017.

Shire's neuroscience unit, anchored by drugs to treat ADHD, may be on the block.

Teva will lay off 7,000 employees by year's end and close 15 plants in the next two years as it tries to offset a deteriorating generics market.

Pfizer announced mixed results in its second quarter, marked by a revenue shortfall on two aging blockbusters.

Dr. Reddy's CEO GV Prasad says the generic drugmaker’s top priority is to do what is needed to get its manufacturing up to FDA expectations.

Could Dupixent end up beating Novartis’ Cosentyx on launch trajectory? The numbers are looking that way so far, a Sanofi executive said Monday.

The U.S. generics pricing picture will get a lot clearer when generics leader Teva reports Thursday, followed by Mylan next week.